Nina Capital

Nina Capital is a healthtech-focused early-stage firm based in Barcelona, writing checks of $250K to $1M at pre-seed, seed, and Series A. The firm invests across Europe and selectively elsewhere, with a sharp focus on companies building software and AI for healthcare workflows. Founders should expect the firm to engage in detail on clinical context and workflow design rather than treating healthcare as a generic vertical, which compresses diligence when the founder has actually thought through implementation.

The thesis covers digital health, health IT and healthcare software, and AI and machine learning in healthcare. Nina is most interested in companies addressing workflow and operational problems inside hospitals, clinics, and life-sciences organizations, including clinical decision support, diagnostic interpretation, operational efficiency, and AI-enabled clinical and administrative tooling. The firm is comfortable with B2B software companies selling into European health systems and with companies whose initial market is European but whose long-term ambition extends into the US. Pre-revenue companies are welcome if the team has clinical or technical depth and a credible commercialization plan.

Check sizes of $250K to $1M place Nina as an early-check investor, often participating in pre-seed and seed rounds led by larger funds and occasionally leading the smallest rounds. The geographic focus is Europe, with concentrations in Spain, the broader EU, the UK, and Israel. Founders should expect questions about regulatory pathways, particularly around the EU MDR and AI Act, and about how the company plans to handle clinical validation and reimbursement in fragmented European health systems. Conversations move quickly when founders have thought carefully about implementation realities.

The team is small and healthtech-native, with backgrounds spanning venture investing, healthcare operating roles, and clinical contexts. Partners do their own diligence and engage directly with founders throughout the process, which means there are no analyst-led screens and no surprises about who actually controls the decision. The firm has built a network of clinical advisors, health-system partners, and follow-on investors specifically focused on European healthtech.

Nina Capital’s working style is engaged and operator-friendly. The fund takes board observer roles in most investments and engages closely on commercial strategy, particularly around how to sell into European health systems and how to design pilots that produce evidence credible to clinical buyers. The firm co-invests with European and US healthcare-focused VCs and has supported portfolio companies through follow-on rounds with larger investors. Founders building healthtech software or AI in Europe, and who want a small, healthcare-native firm that engages on the actual mechanics of clinical sales, will find Nina Capital a credible early partner. Founders pursuing pure consumer wellness or non-clinical wellness plays will find less alignment.